Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017093443) MELFLUFEN DOSAGE REGIMENS FOR CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/093443 International Application No.: PCT/EP2016/079511
Publication Date: 08.06.2017 International Filing Date: 01.12.2016
IPC:
A61K 31/223 (2006.01) ,A61K 31/573 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
22
of acyclic acids, e.g. pravastatin
223
of alpha-amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573
substituted in position 21, e.g. cortisone, dexamethasone, prednisone
Applicants:
ONCOPEPTIDES AB [SE/SE]; Västra Trädgårdsgatan 15 111 53 Stockholm, SE
Inventors:
LINDBERG, Jakob; SE
Agent:
COGGINS, Julia Frances; GB
BRADY, Paul Andrew; GB
SCOTT, Susan Margaret; GB
PEARSON, Samuel John; GB
Priority Data:
1521217.801.12.2015GB
Title (EN) MELFLUFEN DOSAGE REGIMENS FOR CANCER
(FR) RÉGIMES POSOLOGIQUES DE MELFLUFEN POUR LE CANCER
Abstract:
(EN) The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4- fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).
(FR) La présente invention concerne le melflufen (melphalan flufénamide; ester éthylique de L-melphalanyl-4-fluoro-L-phénylalanine), ou un sel de celui-ci, pour utilisation dans le traitement ou la prophylaxie du myélome multiple, une dose de melflufen (à l'exclusion de la masse d'un sel éventuel) étant administrée sous la forme d'une dose parentérale à un débit de perfusion compris entre 1,0 et 1,8 mg/min. L'invention concerne en outre le melflufen, ou un sel de celui-ci, pour utilisation dans le traitement ou la prophylaxie d'un cancer, par exemple un cancer solide, une dose de melflufen étant administré sous la forme d'une dose parentérale à un débit de perfusion inférieur à 0,8 mg/min (par exemple 0,3 à 1,0 mg/min ou, par exemple, 0,3 à 0,8 mg/min).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3003102SG11201803551YAU2016363591CN108289876KR1020180087254EP3383385
MX2018006706US20180369141BR112018010012